Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
Forces of globalization and innovation that have been rippling through our economy for more than 200 years are now ripping up the established terrain of many economic sectors. Whether driven by improvements in computers, biotechnology, communications or other technologies, tumbling...
The Federal Trade Commission today issued the final agenda for its one-day public workshop on competition and follow-on biologics, which will be held on February 4 at its Conference Center located at 601 New Jersey Ave., NW, in Washington, DC.
Federal Trade Commission staff, in response to a request from Massachusetts State Representative Kay Khan, provided comments on Massachusetts House Bill 2009, stating that, as proposed, the elimination of certain supervision requirements for nurse practitioners (NPs) and nurse anesthetists (NAs)...
This will come as no shock to anyone familiar with the Federal Trade Commission’s policy and advocacy function: FTC staff has a long history of advocating for effective competition and consumer protection in electricity markets.
The Federal Trade Commission staff submitted a reply comment in response to a request from the District of Columbia Public Service Commission (DC PSC) for comments on Potomac Electric Power Company’s (Pepco’s) proposed dynamic pricing program for residential customers.
The Federal Trade Commission announced its one-day public workshop on competition and follow-on biologics has been rescheduled for Feb. 4, 2014. The workshop will be held at the FTC’s Conference Center located at 601 New Jersey Ave., NW, in Washington, and will examine competition issues...
Due to inclement weather and the closure of the federal government for today, the Federal Trade Commission has postponed until further notice its one-day public workshop on Follow-On Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin,...
Welcome to Competition Matters, the FTC’s newest blog for all things competition. We hope to become your go-to spot for the latest insights and events from the Bureau of Competition, the Bureau of Economics, and the Office of Policy Planning. We’ll also have occasional missives from...
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.” The workshop will be held in the FTC Conference Center at 601 New Jersey Ave., N.W., in W
The Federal Trade Commission has extended the deadline for public comments on its proposed study of patent assertion entities (PAEs), which it announced on September 27. To provide additional time for interested parties to submit comments on the proposed study, the deadline has been extended...
The Federal Trade Commission held a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop focused on a few key issues, inter alia:
Series of hearings:
December 5, 2008
February 11-12, 2009
March 18-19, 2009
April 17, 2009
May 4-5, 2009
The Federal Trade Commission, the nation’s consumer protection agency, hosted a roundtable to discuss how to empower and protect consumers from scammers with the advent of healthcare marketplaces opening this fall under the Affordable Care Act (ACA).
The Federal Trade Commission will host a one-day public workshop on December 10, 2013, at its headquarters in Washington, DC, to examine competition issues surrounding biologic and follow-on biologic medications.
The FTC will hold hearings this fall to address whether there have been broad-based changes in the contemporary competitive environment that require any adjustments in antitrust and consumer protection enforcement in order to keep pace with those changes.
A series of FTC and DOJ hearings.
The Federal Trade Commission and Department of Justice will commence public hearings in Washington, D.C. on February 26, 2003 on the implications of competition law and policy for health care financing and delivery. The hearings will broadly consider the impact of competition law and...